Traders Purchase High Volume of Call Options on ImmunityBio (NASDAQ:IBRX)

ImmunityBio, Inc. (NASDAQ:IBRX) saw unusually large options trading on Thursday. Stock investors bought 8,015 call options on the stock. This is an increase of 36% compared to the average volume of 5,894 call options.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. EF Hutton Acquisition Co. I upgraded shares of ImmunityBio to a “strong-buy” rating in a research note on Wednesday, October 23rd. BTIG Research assumed coverage on shares of ImmunityBio in a report on Friday, January 10th. They issued a “buy” rating and a $6.00 price target for the company. Finally, D. Boral Capital restated a “buy” rating and issued a $30.00 price target on shares of ImmunityBio in a research report on Thursday.

ImmunityBio Trading Up 27.2 %

Shares of NASDAQ:IBRX opened at $3.04 on Friday. ImmunityBio has a 1-year low of $2.28 and a 1-year high of $10.53. The firm has a market capitalization of $2.12 billion, a PE ratio of -3.30 and a beta of 0.86. The business’s 50 day moving average is $3.78 and its 200-day moving average is $4.26.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of IBRX. Captrust Financial Advisors bought a new stake in ImmunityBio in the 3rd quarter valued at $41,000. Algert Global LLC acquired a new stake in shares of ImmunityBio during the 2nd quarter valued at about $86,000. Virtu Financial LLC bought a new stake in ImmunityBio in the third quarter valued at about $51,000. Dimensional Fund Advisors LP acquired a new position in ImmunityBio in the second quarter worth about $105,000. Finally, Mercer Global Advisors Inc. ADV acquired a new position in ImmunityBio in the second quarter worth about $126,000. 8.58% of the stock is owned by institutional investors.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.